原发性中枢神经系统淋巴瘤治疗方案的探讨  

Discuss of Treatment in Primary Central Nervous System Lymphoma

作　　者：毕中秋 陈亚凤[1] 田垚垚[1] 翟晓菲[1] 王树叶[1] 

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2015年第19期3786-3788,共3页Progress in Modern Biomedicine

基　　金：黑龙江省教育厅科学技术研究项目(12521179)

摘　　要：原发性中枢神经系统淋巴瘤(Primary central nervous system lymphoma,PCNSL)是仅累及中枢神经系统而全身其他部位未发现的结外非霍奇金淋巴瘤,发病率较低,进展快,死亡率高,其主要原因是中枢神经系统是淋巴瘤细胞抵抗化疗药物的一个避难所,血脑屏障通透性升高为淋巴瘤发生转移的重要机制之一[1],但其通透性升高机制尚不明确。其治疗和预后的观念不断发生变化,因此探讨最佳的治疗方案是本文的重点。The primary central nervous system lymphoma （Primary central nervous system lymphoma, PCNSL） is only involved in other parts of the central nervous system and the body is not found in extranodal non-Hodgkin＇s lymphoma,It is low incidence, rapid progression and high death rate. Because of the central nervous system lymphoma ceils resistant to chemotherapy drugs a refuge, BBB permeability increases as one of the important mechanisms for the transfer of lymphoma, but the mechanism is still unclear.The treatment and prognosis of the concept is changing, so explore the best treatment is the focus of this article.

关 键 词：原发性中枢神经系统淋巴瘤 治疗方案 

分 类 号：R739.4[医药卫生—肿瘤]